Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: June Update

Performance overview
Value at beginning of month: $168,030.78
Value at end of month: $160,174.44
Month over month change: -4.67%
Total IRR: 38.03%

Related indices, monthly change
NASDAQ: -0.58%
IVV (iShares Core S&P 500): -0.43%
IBB (iShares NASDAQ Biotechnology Index): +1.28%
MXI (iShares Global Materials): -3.21%
VEGI (iShares MSCI Global Agriculture Producers): -1.89%
ICLN (iShares Clean Energy): -8.39%

Individual performances


Regenxbio led the index in growth after their gene therapy treatment received a Fast Track designation from the FDA. Amyris also exhibited significant growth this month thanks to a number of new collaborations it entered into. It seems that there are many companies that are interested in working with Amyris’s new technology. Most of the rest of the index fell during the month. This was led by Ziopharm, due to a clinical hold that the FDA claced on their Phase I trial, and Arcadia, due to a secondary offering of shares.

Changes made to index

Added CRISPR Therapeutics to the index.

You can view the index here.

Allocation as of June 29, 2018


Calvin Schmidt Synthetic Biology Index: July Update

Calvin Schmidt Synthetic Biology Index: May Update